Consolidative thoracic radiotherapy improves the prognosis of extensive stage small-cell lung cancer patients in the chemoimmunotherapy era: a multicenter retrospective analysis
Background For extensive-stage small cell lung cancer (ES-SCLC) with intrathoracic residuals after chemotherapy, the landmark CREST trial demonstrated the benefit of consolidative thoracic radiotherapy (cTRT). Yet the efficacy and safety of cTRT after chemoimmunotherapy for ES-SCLC remain largely un...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2025-12-01
|
| Series: | Annals of Medicine |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/07853890.2025.2542434 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Background For extensive-stage small cell lung cancer (ES-SCLC) with intrathoracic residuals after chemotherapy, the landmark CREST trial demonstrated the benefit of consolidative thoracic radiotherapy (cTRT). Yet the efficacy and safety of cTRT after chemoimmunotherapy for ES-SCLC remain largely unknown. This study aimed to assess the role of cTRT following chemoimmunotherapy in patients with ES-SCLC.Methods A retrospective analysis of ES-SCLC patients without disease progression after first-line chemoimmunotherapy was conducted between March 2019 and November 2021. Based on whether cTRT or not, patients were allocated to cTRT group or non-cTRT group. We evaluated efficacy by using the median overall survival (mOS) and progression-free survival (mPFS) times, and safety by measuring the incidence of adverse events.Results During this study, 72 patients with ES-SCLC were enrolled, with a median follow-up of 34.66 months. Twenty-nine patients received cTRT and 43 patients did not receive cTRT. Among the cTRT group and the non-cTRT group, the mPFS was 11.50 and 8.02 months, respectively, with a HR of 0.60 (95% CI 0.36–0.99, p = 0.043). The mOS in the cTRT group was also significantly longer than that in the non-cTRT group (28.68 months vs. 16.30 months, HR = 0.56, 95% CI 0.32–0.96, p = 0.033). Based on multivariate analysis, cTRT and cycles of immunotherapy ≥ 6 were independent factors affecting survival. There were no treatment-related deaths and most adverse events were grade 1–2.Conclusions This study suggests that the addition of cTRT to first-line chemoimmunotherapy significantly improves survival in ES-SCLC with well-tolerated toxicity. |
|---|---|
| ISSN: | 0785-3890 1365-2060 |